Zoetis - ZTS Stock Forecast, Price & News

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Stock Down 2.6 %

Shares of Zoetis stock opened at $169.55 on Wednesday. The business's fifty day moving average price is $171.81 and its two-hundred day moving average price is $180.80. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.18 and a quick ratio of 1.46. The company has a market capitalization of $79.37 billion, a P/E ratio of 38.45, a PEG ratio of 2.98 and a beta of 0.73. Zoetis has a 1-year low of $154.18 and a 1-year high of $249.27.

Zoetis (NYSE:ZTS - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The firm had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the prior year, the firm posted $1.19 EPS. The firm's quarterly revenue was up 7.8% on a year-over-year basis. As a group, research analysts forecast that Zoetis will post 5.01 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be paid a $0.325 dividend. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Wednesday, July 20th. Zoetis's dividend payout ratio is presently 29.48%.

Analyst Ratings Changes

ZTS has been the subject of several research reports. Piper Sandler initiated coverage on Zoetis in a research report on Monday, July 11th. They issued an "overweight" rating and a $205.00 target price for the company. Stifel Nicolaus reduced their price objective on Zoetis from $275.00 to $225.00 and set a "buy" rating for the company in a research report on Friday, June 24th. The Goldman Sachs Group reduced their price objective on Zoetis from $208.00 to $202.00 and set a "buy" rating for the company in a research report on Thursday, July 21st. William Blair restated an "outperform" rating on shares of Zoetis in a research report on Friday, August 5th. Finally, StockNews.com lowered Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 26th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $224.14.

Insider Transactions at Zoetis

In other news, CEO Kristin C. Peck sold 9,689 shares of the business's stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now owns 39,743 shares of the company's stock, valued at approximately $7,153,740. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Kristin C. Peck sold 9,689 shares of the business's stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the sale, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at $7,153,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 2,167 shares of the business's stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the sale, the executive vice president now directly owns 23,687 shares in the company, valued at $4,269,818.62. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,356 shares of company stock valued at $3,250,158. Corporate insiders own 0.12% of the company's stock.